|Positive WB detected in||HepG2 cells|
|Western Blot (WB)||WB : 1:500-1:1000|
|Sample-dependent, check data in validation data gallery|
The immunogen of 25175-1-AP is Glypican 3 Fusion Protein expressed in E. coli.
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Glypican 3 fusion protein Ag10129|
|Full Name||glypican 3|
|Calculated molecular weight||580 aa, 66 kDa|
|Observed molecular weight||66 kDa|
|GenBank accession number||BC035972|
|Gene ID (NCBI)||2719|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Glypicans (GPCs) are a family of glycosylphosphatidylinositol (GPI)-anchored heparan sulphate proteoglycans (HSPGs) that may play a role in the control of cell division and growth regulation. In mammals, there are six GPCs (GPC1 to GPC6), all of which have a similar core-protein size of approx. 60 kDa and the clustering of glycosaminoglycan attachment site near the C-terminus. They are tethered to the cell surface by GPI linkages, which can be cleaved by endogenous phospholipases, thus releasing the protein. Glypican 3 (GPC3) is highly expressed in many tissues during development and plays an important role in the regulation of embryonic growth (PMID: 22467855). Loss-of-function mutations of GPC3 result in the Simpson-Golabi-Behmel overgrowth syndrome (SGBS), and Gpc-3 null mice display developmental overgrowth (PMID: 8589713; 18477453). In hepatocellular carcinoma (HCC), the overexpression of glypican 3 has been demonstrated to be a reliable diagnostic indicator (PMID: 19212669; 22706665). The calculated molecular weight of native glypican 3 is 66 kDa, glycanated forms of glypican 3 have higher molecular weights than 66 kDa (PMID: 12851874; 16024626; 19574424).
TCF11 Has a Potent Tumor-Repressing Effect Than Its Prototypic Nrf1α by Definition of Both Similar Yet Different Regulatory Profiles, With a Striking Disparity From Nrf2.
Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity.
hPCL3s promotes hepatocellular carcinoma metastasis by activating β-catenin signaling.